New fda approved weight loss drug belviq
The recommended daily dose of Qsymia contains 7. Phentermine is indicated for short-term weight loss in overweight or obese adults who are exercising and eating a reduced calorie diet. Qsymia is also available at a higher dose (15 mg phentermine and 92 mg of topiramate extended-release) for select patients. Activation of this receptor may help a person eat less and feel full after eating smaller amounts of food. The approved labeling for Belviq recommends that the drug be discontinued in patients who fail to lose 5 percent of their body weight after 12 weeks of treatment, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment. Treatment with Belviq may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. The safety and efficacy of Qsymia were evaluated in two randomized, placebo-controlled trials that included approximately 3,700 obese and overweight patients with and without significant weight-related conditions treated for one year. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. All participants received lifestyle modification that consisted of a reduced calorie diet and exercise counseling. About 47 percent of patients without type 2 diabetes lost at least 5 percent of their body weight compared with about 23 percent of patients treated with placebo. This content has not been altered or updated since it was archived. This content has not been altered or updated since it was archived.
Topiramate is indicated to treat certain types of seizures in people who have epilepsy and to prevent migraine headaches. Compared with placebo, treatment with Belviq for up to one year was associated with average weight loss ranging from 3 percent to 3. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and every month while using the drug and should use effective contraception consistently while taking Qsymia. All patients received lifestyle modification that consisted of a reduced calorie diet and regular physical activity. Data show that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate). Females of reproductive potential must not be pregnant when starting Qsymia therapy or become pregnant while taking Qsymia. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). The content on this page is provided for reference purposes only. In people with type 2 diabetes, about 38 percent of patients treated with Belviq and 16 percent treated with placebo lost at least 5 percent of their body weight. Belviq works by activating the serotonin 2C receptor in the brain. 7 percent. The content on this page is provided for reference purposes only. 5 milligrams of phentermine and 46 mg of topiramate extended-release. Qsymia must not be used during pregnancy because it can cause harm to a fetus. Belviq treatment was associated with favorable changes in glycemic control in those with type 2 diabetes.
New fda approved weight loss drug belviq video:
brand-new fda authorize weight loss agent belviq tags:
new fda approved weight loss drug belviq coupons
New fda approved weight loss drug belviq
